1h Free Analyst Time
According to the recently published report 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.
The report 'Collagenase 3 - Drugs In Development, 2022' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease, Oncology, Respiratory and Toxicology which include indications Osteoarthritis, Osteoarthritis Pain, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chemotherapy Induced Peripheral Neuropathy, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Multiple Myeloma (Kahler Disease), Myocardial Infarction and Seasonal Allergic Rhinitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
- Aquilus Pharmaceuticals Inc
- Avantyx Pharmaceuticals LLC
- Paradigm Biopharmaceuticals Ltd
- Pharmahungary Group
- SteroTherapeutics LLC
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
- Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis - Drug Profile
- Product Description
- Mechanism Of Action
- Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Matrix Metalloproteinase 13 (MMP-13) Inhibitors - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pentosan polysulfate sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
- Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
- Featured News & Press Releases
- Aug 08, 2022: MPS clinical program update and paradigm to present at the International Conference on lysosomal diseases
- Jul 13, 2022: Paradigm partners with NFL Alumni Health on osteoarthritis program
- Jul 06, 2022: Paradigm reports important global progress for the PARA_OA_002 phase 3 clinical trial evaluating Zilosul for osteoarthritis.
- Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment
- May 24, 2022: Paradigm Biopharmaceuticals spotlights potential breakthrough osteoarthritis treatment at Biological Association 3rd Annual Summit
- May 05, 2022: Paradigm doses first subjects in Phase III knee osteoarthritis trial
- Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program
- Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
- Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
- Feb 11, 2022: International researchers highlight the need for PPS as a new adjunct therapy treatment for unmet needs of patients with MPS VI
- Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
- Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
- Dec 16, 2021: PPS treatment demonstrates improvement in heart function and tissue preservation in preclinical heart failure model
- Nov 23, 2021: Positive interim data from phase 2 rare disease trial presented at international medical congress
- Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Aquilus Pharmaceuticals Inc, 2022
- Pipeline by Avantyx Pharmaceuticals LLC, 2022
- Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
- Pipeline by Pharmahungary Group, 2022
- Pipeline by SteroTherapeutics LLC, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aquilus Pharmaceuticals Inc
- Avantyx Pharmaceuticals LLC
- Paradigm Biopharmaceuticals Ltd
- Pharmahungary Group
- SteroTherapeutics LLC
